MacroGenics (MGNX) vs Prelude Therapeutics (PRLD)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 10, 2026.
Summary
Prelude Therapeutics (PRLD) has outperformed MacroGenics (MGNX) over the past year, gaining 177.9% versus a gain of 113.7%. Over five years, PRLD leads with a -76.1% price change compared with -81.1% for MGNX. Prelude Therapeutics is the larger company by market cap ($310.4 million vs $238.2 million), about 1.3 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | MGNX | PRLD |
|---|---|---|
| Share price | $3.74 | $3.89 |
| Market cap | $238.24M | $310.44M |
| 1-day change | +5.35% | +0.26% |
| YTD return | +132.30% | +34.14% |
| 1-year return | +113.71% | +177.86% |
| 5-year return | -81.05% | -76.08% |
| EPS (TTM) | $-1.70 | $-0.73 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $5.08 | $6.83 |
| 52-week low | $1.29 | $1.16 |
| Distance from 52-week high | -26.38% | -43.05% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +113.90% | +136.50% |
| Average volume | 622.92K | 477.67K |
| Shares outstanding | 63.70M | 65.08M |
| Employees | 293 | 79 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- PRLD has outperformed MGNX by 64.1 percentage points over the past year.
About MacroGenics
MGNX stock →MacroGenics, Inc., a clinical-stage biopharmaceutical company, discovers, develops, manufactures, and commercializes antibody-based therapeutics for the treatment of cancer in the United States. The company's product pipeline includes lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4 for the treatment of mCRPC and docetaxel that is in phase 2 clinical trials, as well as for the treatment of platinum-resistant ovarian cancer and clear cell gynecologic cancer which has completed phase 1 clinical trial; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload; MGC028, an antibody-drug conjugates (ADC) that targets ADAM9 and delivers a novel TOP1i-based linker-payload for the treatment of solid tumors, which is in phase 1 clinical trials; MGC030, a ADC molecule that targets an undisclosed antigen expressed across several solid tumors, which is in preclinical trials.
Health Care · Biotechnology: Pharmaceutical Preparations · 293 employees
About Prelude Therapeutics
PRLD stock →Prelude Therapeutics Incorporated, a clinical-stage precision oncology company, focuses on the discovery and development of novel precision cancer medicines to underserved patients. It is developing JAK2V617F, a driver mutation product for the treatment of myeloproliferative neoplasms, myelofibrosis (MF), polycythemia vera, and essential thrombocythemia (ET); KAT6A for the treatment of advanced breast cancer and other solid tumors; and mutated calreticulin degrader antibody conjugates to treat MF and ET.
Health Care · Biotechnology: Pharmaceutical Preparations · 79 employees
MGNX vs PRLD FAQ
Which is bigger, MacroGenics or Prelude Therapeutics?
Prelude Therapeutics (PRLD) is larger, with a market capitalization of $310.44M compared with $238.24M for MacroGenics (MGNX).
Which stock has performed better over the past year, MGNX or PRLD?
PRLD returned +177.86% over the past 12 months, compared with +113.71% for MGNX (price return, excluding dividends). Past performance does not predict future results.
Are MacroGenics and Prelude Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.